Current evidence and clinical implications of aspirin resistance

Journal of Vascular Surgery

Volumn 50, Issue 6, 2009, Pages 1500-1510

  Kasotakis, George ^a   Pipinos, Iraklis I ^b   Lynch, Thomas G ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BILIRUBIN; CD31 ANTIGEN; CD40 LIGAND; CD51 ANTIGEN; CD61 ANTIGEN; CD63 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG METABOLITE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; LIOTHYRONINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; PENICILLIN G; PHENYTOIN; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SULFINPYRAZONE; THROMBOXANE A2; THYROXINE; UNINDEXED DRUG; URIC ACID; VERY LATE ACTIVATION ANTIGEN 2; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ATHEROGENESIS; BINDING SITE; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; BRAIN CIRCULATION; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CORONARY ARTERY; CORONARY ARTERY DISEASE; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; ENZYME ASSAY; FLOW CYTOMETRY; GOLD STANDARD; HEMOSTASIS; HUMAN; HYPOPROTEINEMIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL CIRCULATION; PERIPHERAL VASCULAR DISEASE; PLASMA PROTEIN BINDING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR SURGERY;

ASPIRIN; BLEEDING TIME; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; VASCULAR SURGICAL PROCEDURES;

EID: 70649084103     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.06.023     Document Type: Review

References (114)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
4. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
5. McCabe D.J., Harrison P., Mackie I.J., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16 (2005) 269-280
6. Berrouschot J., Schwetlick B., von Twickel G., et al. Aspirin resistance in secondary stroke prevention. Acta Neurologica Scandinavica 113 (2006) 31-35
7. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., and Brace L.D. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
8. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
9. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
10. Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108 (2003) 542-547
11. Yilmaz M.B., Balbay Y., Caldir V., Ayaz S., Guray Y., Guray U., and Korkmaz S. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 115 (2005) 25-29
12. Buchanan M.R. Biological basis and clinical implications of acetylsalicylic acid resistance. Can J Cardiol 22 (2006) 149-151
13. Buchanan M.R. Acetylsalicylic acid resistance and clinical outcome-the Hobikoglu study is worth noting. Can J Cardiol 23 (2007) 207-208
14. Poston R.S., Gu J., Brown J.M., et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 131 (2006) 122-130
15. Chen W.H., Lee P.Y., Ng W., et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 96 (2005) 760-763
16. Zhang Y., Liang J., Zhou Y.J., Yuan H., Zhang Y.Z., and Dong L. Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention. [Article in Chinese] Zhonghua Xin Xue Guan Bing Za Zhi (Chinese J Cardiovasc Dis) 33 (2005) 695-699
17. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
18. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
19. Macchi L., Christiaens L., Brabant S., et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 42 (2003) 1115-1119
20. Christiaens L., Macchi L., Herpin D., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 108 (2002) 115-119
21. Pamukcu B., Oflaz H., and Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 149 (2005) 675-680
22. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., and Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
23. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
24. Friend M., Vucenik I., and Miller M. Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326 (2003) 82-83
25. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709
26. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., and Lau C.P. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
27. Borna C., Lazarowski E., van Heusden C., Ohlin H., and Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 3 (2005) 10
28. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
29. Hobikoglu G.F., Norgaz T., Aksu H., Ozer O., Erturk M., Nurkalem Z., and Narin A. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 207 (2005) 59-64
30. Stejskal D., Prosková J., Lacnák B., et al. [Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications]. [Article in Czech] Vnitr Lek 50 (2004) 591-599
31. Faraday N., Braunstein J.B., Heldman A.W., Bolton E.D., Chiles K.A., Gerstenblith G., and Schulman S.P. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 15 (2004) 9-14
32. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., and DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
33. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 147 (2004) 293-300
34. Sane D.C., McKee S.A., Malinin A.I., and Serebruany V.L. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 90 (2002) 893-895
35. Payne D.A., Jones C.I., Hayes P.D., Webster S.E., Ross Naylor A., and Goodall A.H. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?. Thromb Haemost 92 (2004) 89-96
36. Assadian A., Lax J., Meixner-Loicht U., Hagmüller G.W., Bayer P.M., and Hübl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 45 (2007) 1142-1147 discussion 1147
37. Ziegler S., Maca T., Alt E., Speiser W., Schneider B., and Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13 (2002) 493-497
38. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
39. Malinin A., Spergling M., Muhlestein B., Steinhubl S., and Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 (2004) 295-301
40. Wang J.C., Aucoin-Barry D., Manuelian D., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 (2003) 1492-1494
41. Marshall P.W., Williams A.J., Dixon R.M., Growcott J.W., Warburton S., Armstrong J., and Moores J. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 44 (1997) 151-155
42. Hillarp A., Lethagen S., and Mattiasson I. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. J Thromb Haemost 1 (2003) 196-197
43. Jack D.B. One hundred years of aspirin. Lancet 350 (1997) 437-439
44. The Royal Society of London. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edmund Stone, of Chipping-Norton in Oxfordshire. Philos Trans R Soc Lond 53 (1763) 195-200
45. Sneader W. The discovery of aspirin: a reappraisal. BMJ 321 (2000) 1591-1594
46. Craven L.L. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 75 (1953) 38-44
47. Furie B., and Furie B.C. Mechanisms of thrombus formation. N Engl J Med 359 (2008) 938-949
48. Palabrica T., Lobb R., Furie B.C., et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359 (1992) 848-851
49. Roth G.J., and Calverley D.C. Aspirin, platelets, and thrombosis: theory and practice. Blood 83 (1994) 885-898
50. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
51. Brunton L., Lazo J., and Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics (2005), McGraw-Hill Professional
52. Hankey G.J., and Eikelboom J.W. Antiplatelet drugs. Med J Aust 178 (2003) 568-574
53. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
54. Homoncik M., Jilma B., Hergovich N., Stohlawetz P., Panzer S., and Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83 (2000) 316-321
55. Serebruany V.L., Malinin A.I., Oshrine B.R., Sane D.C., Takserman A., Atar D., and Hennekens C.H. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res 113 (2004) 197-204
56. Hézard N., Metz D., Nazeyrollas P., Droullé C., Potron G., and Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?. Thromb Res 108 (2002) 43-47
57. Michelson A.D. Methods for the measurement of platelet function. Am J Cardiol 103 3 Suppl (2009) 20A-26A
58. Schwartz K.A., Schwartz D.E., Barber K., Reeves M., and De Franco A.C. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 6 (2008) 46
59. Johnson S.B. Methodological issues in diabetes research. Measuring adherence. Diabetes Care 15 (1992) 1658-1667
60. Shantsila E., and Lip G.Y. 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?. J Transl Med 6 (2008) 47
61. Carney R.M., Freedland K.E., Eisen S.A., Rich M.W., Skala J.A., and Jaffe A.S. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med 24 (1998) 35-39
62. Dalen J.E. Aspirin resistance: is it real?. Is it clinically significant?. Am J Med 120 (2007) 1-4
63. Dalen J.E. Is aspirin resistance due to noncompliance?. Arch Intern Med 168 (2008) 550 author reply 550
64. Maclouf J., Folco G., and Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 79 (1998) 691-705
65. Santos M.T., Moscardó A., Vallés J., et al. Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets. Circulation 102 (2000) 1924-1930
66. Gerschutz G.P., Bhatt D.L., and The Clopidogrel in Unstable Angina to Prevent Recurrent Events study. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?. Am Heart J 145 (2003) 595-601
67. Kawasaki T., Ozeki Y., Igawa T., and Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31 (2000) 591-595
68. Furman M.I., Benoit S.E., Barnard M.R., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31 (1998) 352-358
69. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
70. Bojesen S.E., Juul K., Schnohr P., Tybjaerg-Hansen A., Nordestgaard B.G., and Copenhagen City Heart Study. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 42 (2003) 661-667
71. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101 (2000) 1013-1018
72. Undas A., Brummel K., Musial J., Mann K.G., and Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104 (2001) 2666-2672
73. Andrioli G., Minuz P., Solero P., Pincelli S., Ortolani R., Lussignoli S., and Bellavite P. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 110 (2000) 911-918
74. Samani N.J., and Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 33 (1997) 693-697
75. Weiss E.J., Bray P.F., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334 (1996) 1090-1094
76. Mikkelsson J., Perola M., Laippala P., Penttilä A., and Karhunen P.J. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 36 (2000) 1317-1323
77. Schönbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
78. Patrignani P., Sciulli M.G., Manarini S., Santini G., Cerletti C., and Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 50 (1999) 661-667
79. Rocca B., Secchiero P., Ciabattoni G., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 99 (2002) 7634-7639
80. Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., and Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 353 (1999) 900
81. Cipollone F., Rocca B., and Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24 (2004) 246-255
82. Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P.P., and Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984
83. Burch J.W., Stanford N., and Majerus P.W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61 (1978) 314-319
84. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
85. FitzGerald G.A., Oates J.A., Hawiger J., Maas R.L., Roberts II L.J., Lawson J.A., and Brash A.R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71 (1983) 676-688
86. De Caterina R., Giannessi D., Boem A., et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 54 (1985) 528-532
87. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 234S-264S
88. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Baggish J.S., Bhatt D.L., and Topol E.J. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
89. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., and Brace L.D. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
90. Hurlen M., Seljeflot I., and Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 32 (1998) 233-237
91. Abaci A., Yilmaz Y., Caliskan M., Bayram F., Cetin M., Unal A., and Cetin S. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res 116 (2005) 465-470
92. von Pape K.W., Strupp G., Bonzel T., and Bohner J. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 94 (2005) 889-891
93. Dippel D.W., Van Kooten F., Leebeek F.W., van Vliet H.H., Mehicevic A., Li S.S., and Koudstaal P.J. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?. Cerebrovasc Dis 17 (2004) 296-302
94. Hart R.G., Leonard A.D., Talbert R.L., Pearce L.A., Cornell E., Bovill E., and Feinberg W.M. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23 (2003) 579-584
95. Cerletti C., Dell'Elba G., Manarini S., et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 42 (2003) 1059-1070
96. Tohgi H., Konno S., Tamura K., Kimura B., and Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23 (1992) 1400-1403
97. Quinn M.J., Aronow H.D., Califf R.M., et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 43 (2004) 972-978
98. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
99. Akopov S.S., Grigorian G.S., and Gabrielian E.S. Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. J Clin Pharmacol 32 (1992) 133-135
100. Pappas J.M., Westengard J.C., and Bull B.S. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118 (1994) 801-804
101. Williams F.M., Mutch E.M., Nicholson E., Wynne H., Wright P., Lambert D., and Rawlins M.D. Human liver and plasma aspirin esterase. J Pharm Pharmacol 41 (1989) 407-409
102. Hung J., Lam J.Y., Lacoste L., and Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
103. Alexander J.H., Harrington R.A., Tuttle R.H., et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 83 (1999) 1147-1151
104. Santopinto J., Gurfinkel E.P., Torres V., et al. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 141 (2001) 566-572
105. Buchanan M.R., and Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11 (1995) 221-227
106. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
107. Lynch T.G., and Pipinos I.I. Invited Commentary. J Vasc Surg 45 (2007) 1147
108. Webster S.E., Payne D.A., Jones C.I., Hayes P.D., Bell P.R., Goodall A.H., and Naylor A.R. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 40 (2004) 463-468
109. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
110. Wong S., Morel-Kopp M.C., Chen Q., Appleberg M., Ward C.M., and Lewis D.R. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 95 (2006) 1042-1043
111. [No authors listed]. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
112. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
113. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
114. Bhatt D.L., Topol E.J., Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263-268